Tevogen Bio’s Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio…
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
February 07, 2025 16:05 ET | Source: AEON Biopharma IRVINE, Calif., Feb.…
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
Matinas BioPharma Receives NYSE Noncompliance Notice
January 10, 2025 17:15 ET | Source: Matinas BioPharma Holdings, Inc. BEDMINSTER,…
Matinas BioPharma Receives NYSE Noncompliance Notice
January 10, 2025 17:15 ET | Source: Matinas BioPharma Holdings, Inc. BEDMINSTER,…
AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
January 06, 2025 09:00 ET | Source: AEON Biopharma IRVINE, Calif., Jan.…
AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
January 06, 2025 09:00 ET | Source: AEON Biopharma IRVINE, Calif., Jan.…
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
January 03, 2025 20:02 ET | Source: AEON Biopharma IRVINE, Calif., Jan.…
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
January 03, 2025 20:02 ET | Source: AEON Biopharma IRVINE, Calif., Jan.…